Clinical momentum Arvinas is a clinical-stage biotech with ongoing programs including vepdegestrant for ER+/HER2- breast cancer, ARV-393 for non-Hodgkin lymphoma, and ARV-102 for neurodegenerative disorders, presenting multiple near-term collaboration and licensing opportunities with pharma partners seeking PROTAC degraders or oncology/neurology assets.

Platform leverage The company’s PROTAC Discovery Engine and proteolysis targeting degrader technology position it as a source for collaboration, licensing, or out-licensing deals with firms looking to augment their degrader pipelines or to co-develop novel targets using Arvinas’ validated platform.

Financial runway With funding around $462 million and revenue in the preliminary range, Arvinas demonstrates financial stability to support collaboration deals, milestone-driven partnerships, and potential co-development agreements that require upfront investment.

Strategic approvals FDA approval momentum for VEPPANU marks a proof point for PROTAC technology, creating sales opportunities in out-licensing, regional partnerships, and expansion of access via pharma distributors or regional commercialization agreements as the program matures.

Investors and growth Active investor interest and recent RSU awards to new hires indicate a growing team and capital market engagement, signaling readiness for expanded business development activities, strategic collaborations, and accelerated deal-making to capitalize on the burgeoning degrader landscape.